trending Market Intelligence /marketintelligence/en/news-insights/trending/N81bAOqY9BKGUG7RIe6oEA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Medicure files patent infringement against Nexus Pharmaceuticals


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Medicure files patent infringement against Nexus Pharmaceuticals

Medicure Inc. filed a suit against Nexus Pharmaceuticals Inc. for allegedly infringing its patent for drug Aggrastat.

Aggrastat, or tirofiban hydrochloride, is used to reduce blood clots in patients with acute coronary syndrome.

Medicure said it filed the case after Nexus sought the U.S. Food and Drug Administration's approval to market a generic version of Medicure's medicine. The patent for Aggrastat has not yet expired.

Medicure, a Canada-based pharmaceutical company, filed the case in the U.S. District Court for the District of Northern District of Illinois through its Medicure International Inc. unit.

Previously, Medicure sued India's Gland Pharma Ltd. for infringing the patent for Aggrastat. The case was settled in August.